Rafael Holdings Inc RFL
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NEW YORK STOCK EXCHANGE, INC. |
| Currency | USD |
| IPO Date | 2018-03-12 |
| Shares Out. | 52,000,000 |
| Website | rafaelholdings.com ↗ |
| Phone | 13026365400 |
| Employees | 23 |
| Revenue | $179,000 |
| Gross Profit | $171,000 |
| Net Income | -$2.9M |
| Free Cash Flow | -$32.0M |
| Total Assets | $92.0M |
| Total Liabilities | $11.2M |
| Equity | $80.8M |
About Rafael Holdings Inc
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.
Rafael Holdings Inc is a publicly traded company under the ticker symbol RFL on the NEW YORK STOCK EXCHANGE, INC., operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.